External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home 2023 ASCO Annual Meeting
Roche and Genentech at

2023 ASCO Annual Meeting

June 02 - June 06
Chicago, USA
am.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:45 PM
Duration 6mins E450
Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study
Petra Budde, Delvys Rodriguez Abreu, Hans-Dieter Zucht, Divya Shrivastava, Annika L. Kilian, Elen Hoglander, Stefaniya Shoshkova, Marija Markovic, Monika Kaul, Jose Vicente Cardona, G Scott Chandler, Rajat Mohindra
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:54 PM
Duration 12mins Virtual
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
Richard S. Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng, Adam Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Ed Gane
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 12mins Hall D1
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: Phase III CONTACT-03 study
Choueiri T, Piotr T, Albiges L, Suárez C, Voss M, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Chan K, Powles T, Gupta S, Kalaitzidou M, Scheffold C, Pal K S, Mochalova A
Oncology | Genitourinary cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 12mins Arie Crown Theater
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Masatoshi Kudo, Minshan Chen, Pierce Chow, Ahmed Kaseb, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:42 PM
Duration 12mins Hall D1
Overall survival by response to first-line induction treatment with atezolizumab + platinum/gemcitabine vs placebo + plt/gem in patients with metastatic urothelial carcinoma: updated data from the IMvigor130 OS final analysis
Grande E, Bamias A, Galsky MD, Kikuchi E, Davis ID, Arranz JA, Rezazadeh Kalebasty A, Garcia del Muro X, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Puente J, Li J-R, Lee C, Bernhard S, Nicholas A, Telliez J, De Santis M
Oncology | Genitourinary cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:24 AM
Duration 20mins S100bc
Clinical value of timely targeted therapy (TT) for advanced non-small cell lung cancer patients (aNSCLC) with actionable driver oncogenes (ADO)
Stricker T, Jain N, Yu E, Ma E, Schuldt R, Wang R, Sussell J, Ogale S, Szado T, LIn V, Price R, Slater D, Vaena D, Staszewski H, Fang B, Seneviratne L, Arrowsmith E, Daniel D
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:36 AM
Duration 20mins S100bc
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the Community Setting
Vidal G, Neha J, Fisher A, Sheinson D, Lofgren K, Ma E Yu E, Comment L, Miksad R, Daniel D
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Presented at this congress:

 

Poster:

Global prevalence of CLDN18.2-positivity in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

Authors: Shitara K, Xu RH, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ajani JA, Shah MA

This file is not available.

Presented at this congress:

 

Poster:

LungFlag, a Machine-Learning (ML) Personalized Tool for Assessing Lung Cancer Risk in a Community Setting, Demonstrates Comparable Performance in Flagging Non-Small Cell Lung Cancer (NSCLC) Regardless of Sex or Race

Authors: Choman EN, Morgenstern D

This file is not available.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.